Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
09/28/2010
Trade Name:
Kapvay Extended Release Tablets
Generic or Proper Name (*):
clonidine
Indications Studied:
Treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications
Therapeutic Category:
Non-stimulant ADHD treatment
Ages Studied:
6-17 years
Study #:
3
Study Type:
Safety
Study Design:
Open Label
No Patients:
303
No Centers:
27
No Countries:
1
BPCA(B), PREA(P):
P
Countries:
US
-
-